Transforming oncology clinical trial matching through neuro-symbolic, multi-agent AI and an oncology-specific knowledge graph: a prospective evaluation in 3804 patients.

Background: Clinical trial enrollment in oncology remains critically low, with fewer than 5% of eligible adults participating, in large part due to the complexity and labor intensity of eligibility screening. We prospectively evaluated a neuro-symbolic, multi-agent artificial intelligence (AI) platform integrating domain-specific large language model (LLM) agents, an oncology-specific knowledge graph, a real-time recommendation engine, and human-in-the-loop review to determine whether automated extraction and reasoning can safely improve trial identification, efficiency, and equity at scale. Methods: Consecutive patients [ Results: The multi-agent neuro-symbolic system achieved an F1 score of 0.82 (95% confidence interval 0.81-0.83). In comparison, the GPT-4 zero-shot baseline achieved an F1 of 0.47, and the GPT-4 chain-of-thought baseline achieved an F1 of 0.67. Per-patient screening time decreased from a median of 120 min (manual review) to ∼30 min total (15 min automated processing + 15 min clinical review). Across the cohort, the system processed 157 000 pages, screened 23 912 candidate patient-trial pairs, and produced 17 912 oncologist-confirmed matches, with median time-to-recommendation <7 days. No demographic subgroup exceeded a 10-percentage point F1 gap; the largest observed difference was ∼7 points between white and black/African American patients. Ablation experiments showed that both knowledge graph grounding and multi-agent decomposition contributed materially to performance and efficiency. Eligibility confidence scores exhibited reasonable calibration in the clinically relevant operating range. Conclusions: A neuro-symbolic, multi-agent architecture that couples LLM-based extraction with ontology-grounded, deterministic eligibility reasoning improved the accuracy, throughput, and timeliness of oncology clinical trial matching versus LLM-only baselines, while preserving clinician oversight and maintaining modest subgroup performance gaps. These results support scalable, equity-aware deployment of AI-assisted trial screening in routine oncology practice.